291 related articles for article (PubMed ID: 24046070)
21. Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.
Jung YJ; Katilius E; Ostroff RM; Kim Y; Seok M; Lee S; Jang S; Kim WS; Choi CM
Clin Lung Cancer; 2017 Mar; 18(2):e99-e107. PubMed ID: 27836219
[TBL] [Abstract][Full Text] [Related]
22. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
23. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
24. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
25. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Yamamoto N; Iida T
Anticancer Res; 2003; 23(3C):2869-74. PubMed ID: 12926125
[TBL] [Abstract][Full Text] [Related]
26. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
[TBL] [Abstract][Full Text] [Related]
27. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
[TBL] [Abstract][Full Text] [Related]
28. The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients.
Zhang X; Ma S; Chen Y; Yin Y; Bai W; Tan J; Shi G
Int J Biol Markers; 2021 Dec; 36(4):27-35. PubMed ID: 34761718
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.
Chen ZQ; Huang LS; Zhu B
Dis Markers; 2018; 2018():9845123. PubMed ID: 30647803
[TBL] [Abstract][Full Text] [Related]
30. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
[TBL] [Abstract][Full Text] [Related]
31. Lactate dehydrogenase and serum tumor markers for predicting metastatic status in geriatric patients with lung adenocarcinoma.
Ren X; Zhang Y; Lyu Y; Jin B; Guo H; Wu J; Li X; Liu X
Cancer Biomark; 2019; 26(2):139-150. PubMed ID: 31356196
[TBL] [Abstract][Full Text] [Related]
32. The Clinical Significance of Serum MASP-2 and IDH1 in the Early Diagnosis of Non-Small Cell Lung Cancer.
Chen Y; Wu ED; Ma S; Bai WQ; Yin YJ; Shi GL
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180422
[TBL] [Abstract][Full Text] [Related]
33. Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study.
Ye S; Chen X; Yao Y; Li Y; Sun R; Zeng H; Shu Y; Yin H
Sci Rep; 2019 Feb; 9(1):2652. PubMed ID: 30804354
[TBL] [Abstract][Full Text] [Related]
34. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
35. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
Li M; Zhang Y; Jiang L; Li Y; Li G; Zhou J; Yang C; Li X; Qu W; Chen Y; Chen Q; Wang S; Xing J; Huang H
Neoplasma; 2022 May; 69(3):729-740. PubMed ID: 35471981
[TBL] [Abstract][Full Text] [Related]
36. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Tan F; Jiang Y; Sun N; Chen Z; Lv Y; Shao K; Li N; Qiu B; Gao Y; Li B; Tan X; Zhou F; Wang Z; Ding D; Wang J; Sun J; Hang J; Shi S; Feng X; He F; He J
Mol Cell Proteomics; 2012 Feb; 11(2):M111.008821. PubMed ID: 22064513
[TBL] [Abstract][Full Text] [Related]
37. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.
Sheng X; Du X; Zhang X; Li D; Lu C; Li Q; Ma Z; Song Q; Wang C
Croat Med J; 2009 Oct; 50(5):455-64. PubMed ID: 19839069
[TBL] [Abstract][Full Text] [Related]
38. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
39. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
40. Clinical value of eukaryotic elongation factor 2 (eEF2) in non-small cell lung cancer patients.
Sun HG; Dong XJ; Lu T; Yang MF; Wang XM
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6533-5. PubMed ID: 24377563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
